Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
July 17, 2018Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
- Current Readout Includes New Six Month Data for Cohort 5 and Aggregate Trial Data - - Results Continue to Demonstrate Favorable Safety Profile, Potential for Durable Cell Engraftment at the Injury Site and Improved Motor Function - - 12 Month Top-Line Readout from the Entire SCiStar Study Expected in First Quarter of 2019 - FREMONT, Calif., July 17, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based thera... 
Printer Friendly Version
July 12, 2018Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke
AST-OPC1 has Demonstrated Positive Safety Profile and Promising Signs of Efficacy in a Phase 1/2a Trial for Severe Spinal Cord Injury FREMONT, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it has entered into an exclusive license agreement with Th... 
Printer Friendly Version
July 11, 2018Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
FREMONT, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced that the Safety Review Committee (SRC) for the first clinical trial of AST-VAC2, held a scheduled meeting to review the safety and tolerability data generated in the first patient enrolled in the st... 
Printer Friendly Version
July 09, 2018OncoCyte Reports Encouraging New Study Results for Lung Cancer Blood Test
- Results suggest improved performance of next-generation test - Study results support move to new diagnostic testing platform - Significant development work required to fully validate this recent progress ALAMEDA, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel tests for early detection of cancer, today reported that its most recent study of clinical samples in the development of DetermaVu™, its lung cancer diagnostic blood test, has... 
Printer Friendly Version
June 12, 2018Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
FREMONT, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced enrollment and dosing of the first subject in the first-in-human Phase 1 clinical trial of AST-VAC2 in the United Kingdom. This initial clinical trial, which is being sponsored, managed and funded by Can... 
Printer Friendly Version
June 05, 2018Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury
- AST-OPC1 Safety Profile Continues To Be Favorable - FREMONT, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that the independent Data Monitoring Committee (DMC) for the company’s SCiStar Phase 1/2a study of AST-OPC1 in acute spinal cord injury has c... 
Printer Friendly Version
May 16, 2018Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress
FREMONT, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Rob Allen, Asterias’ Senior Director of Immunotherapy, will discuss the Company’s cancer immunotherapy product candidate, which is poised to enter the clinic this quarter with the anticipated start o... 
Printer Friendly Version
May 15, 2018OncoCyte Reports First Quarter 2018 Financial Results
Conference Call Today at 4:30 pm ET ALAMEDA, Calif., May 15, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today reported financial and operating results for the first quarter ended March 31, 2018. “We have completed initial sample testing and begun analyzing the data collected in the confirmation study of our DetermaVu™ lung cancer diagnostic test. This study is being conducted on alternative di... 
Printer Friendly Version
May 09, 2018Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
-  AST-VAC2 Immunotherapy Program Prepares to Enter Clinic in Second Quarter of 2018 – - Conference Call and Webcast Today, May 9, at 5:00 p.m. ET – FREMONT, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today reported financial and operational results for the quarter ende... 
Printer Friendly Version
May 08, 2018OncoCyte to Report First Quarter 2018 Financial Results on May 15, 2018
ALAMEDA, Calif, May 08, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the first quarter of 2018, ended March 31, 2018, on Tuesday, May 15, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, May 15, 2018, at 4:30 pm ET / 1:30 pm PT to discuss the results al... 
Printer Friendly Version
May 03, 2018Asterias Biotherapeutics to Report First Quarter 2018 Results on May 9, 2018
FREMONT, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release first quarter 2018 financial and operating results on Wednesday, May 9, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast on... 
Printer Friendly Version
May 02, 2018Asterias Biotherapeutics to Present Safety and Efficacy Data from AST-OPC1 SCiStar Study at the American Spinal Injury Association (ASIA) 2018 Annual Meeting                                                                         
FREMONT, Calif., May 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Edward Wirth III, M.D., Ph.D., Asterias’ Chief Medical Officer, will present previously announced 12-month safety and efficacy results for Cohort 2 (subjects with AIS-A grade cervical spinal cord inj... 
Printer Friendly Version
April 27, 2018Asterias Biotherapeutics to Present AST-OPC1 Program Update at the Upcoming American Society for Neural Therapy and Repair Conference
FREMONT, Calif., April 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Nate Manley, Asterias’ Associate Director of Neurobiology, will present an AST-OPC1 program update at the American Society for Neural Therapy and Repair INTR-15 Conference, which is being held duri... 
Printer Friendly Version
April 25, 2018Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2
-Release of clinical grade lot of AST-VAC2 is key step in Cancer Research UK’s initiation of clinical study in Non-Small Cell Lung Cancer - FREMONT, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Cancer Research UK has released the first cGMP (cur... 
Printer Friendly Version
April 03, 2018Leading Molecular Diagnostics Executive Ronnie Andrews Appointed to OncoCyte’s Board of Directors
ALAMEDA, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX) today announced the appointment of Ronald Andrews, Jr., an executive with over 30 years’ experience in the molecular diagnostics and genomics industries, to the Company’s Board of Directors. The appointment of Mr. Andrews brings the number of directors to seven and the number of independent directors to four. “Ronnie comes to us with an extensive background in the molecular diagnostics industry, str... 
Printer Friendly Version
April 02, 2018OncoCyte Reports Fourth Quarter and Full Year 2017 Financial Results
Development of DetermaVu™ Remains on Track for Completion in 2018 -Conference Call Today at 4:30 pm ET- ALAMEDA, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2017. “Since our last quarterly update to investors in November, the team at OncoCyte has been busy making substanti... 
Printer Friendly Version
April 02, 2018OncoCyte Files Patents for 190 Newly Identified Novel Lung Cancer Biomarkers
New biomarkers could assist in differentiating malignant from benign lung nodules for improved lung cancer diagnosis ALAMEDA, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, strengthened its intellectual property portfolio as it filed global patent applications for 190 newly identified novel biomarkers. These new biomarkers may enhance OncoCyte’s lung cance... 
Printer Friendly Version
April 02, 2018OncoCyte Names Cavan Redmond Chairman of the Board of Directors
ALAMEDA, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX) today announced that Cavan Redmond, a director of the Company since 2015, has been named Chairman of the Board of Directors. Alfred D. Kingsley, who has been Chairman since 2009 and was instrumental in forming OncoCyte and in taking it public in 2015, will remain a director.  Mr. Redmond’s career brings a unique combination of R&D and commercial experience in biotechnology and consumer healthcare. H... 
Printer Friendly Version
March 29, 2018OncoCyte to Report Fourth Quarter and Full Year 2017 Financial Results on April 2, 2018
ALAMEDA, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth quarter and full year 2017, ended December 31, 2017, on Monday, April 2, 2018, after the close of the U.S. financial markets. The Company will host a conference call on Monday, April 2, 2018, at 4:30 p.m. ET / 1:30 p.m. PT to ... 
Printer Friendly Version
March 28, 2018OncoCyte Announces the Closing of a $10 Million Private Placement of Common Stock
ALAMEDA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has closed a private placement of its common stock with two of its current investors. The purchase agreement for the private placement committed the investors to purchase 7,936,508 shares of common stock for $1.26 per share, for total gross proceeds of $10.0 million before deduc... 
Printer Friendly Version
March 15, 2018Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments
- Achieved Meaningful Progress with Key Clinical Programs - - Anticipate Multiple Data Readouts from SCiStar Study in 2018 into First Quarter of 2019 - - Expect to Enroll First Subject in AST-VAC2 Randomized Clinical Trial in NSCLC in Second Quarter - - Conference Call and Webcast Today, March 15, at 5:00 p.m. ET - FREMONT, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics t... 
Printer Friendly Version
March 09, 2018Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018
FREMONT, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:ST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release fourth quarter and full year 2017 financial and operating results on Thursday, March 15, 2018 after the close of the U.S. financial markets. The Company will host a conference c... 
Printer Friendly Version
March 08, 2018OncoCyte Announces Initial Results of DetermaVu™ Feasibility on New Platforms; Enhancements May Increase Lung Cancer Diagnostic Test’s Clinical Performance
Company Anticipates Commercial Launch During 2018 ALAMEDA, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today provided an update on the development and commercial launch timeline of DetermaVu™, its liquid biopsy lung cancer diagnostic test. As reported in November 2017, during the process of running initial samples for the Clinical Validation Study inconsistent ... 
Printer Friendly Version
February 15, 2018Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program
FREMONT, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing regenerative medicine therapeutics to treat neurological conditions associated with de-myelination and cellular immunotherapies to treat cancer, today announced that it has strengthened its global IP portfolio over the past 12 months with the issuance of 46 new patents, including in the United States, Europe, Japan, Canada, China, Australia, Isr... 
Printer Friendly Version
January 04, 2018Asterias Biotherapeutics Reports Milestone Targets for 2018
FREMONT, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company pioneering the field of regenerative medicine, today provided its 2018 milestones targets for its spinal cord injury and cancer immunotherapy programs after successfully achieving its milestones for 2017.  These achievements, combined with the Company’s financial resources position Asterias to achieve the following milestones during 2018. ANTICIPATED 2018 MILESTONES... 
Printer Friendly Version